CN107141346B - Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof - Google Patents
Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof Download PDFInfo
- Publication number
- CN107141346B CN107141346B CN201710480369.0A CN201710480369A CN107141346B CN 107141346 B CN107141346 B CN 107141346B CN 201710480369 A CN201710480369 A CN 201710480369A CN 107141346 B CN107141346 B CN 107141346B
- Authority
- CN
- China
- Prior art keywords
- atledspevi
- antioxidant
- polypeptide
- biologically active
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 121
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 107
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 101
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 44
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 34
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 29
- 230000036541 health Effects 0.000 claims description 13
- 230000007365 immunoregulation Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 8
- 230000004957 immunoregulator effect Effects 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 17
- 238000002474 experimental method Methods 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 15
- 210000002540 macrophage Anatomy 0.000 abstract description 14
- 238000000338 in vitro Methods 0.000 abstract description 13
- 102000004127 Cytokines Human genes 0.000 abstract description 9
- 108090000695 Cytokines Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000003832 immune regulation Effects 0.000 abstract 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 28
- 235000006708 antioxidants Nutrition 0.000 description 23
- 239000011347 resin Substances 0.000 description 21
- 229920005989 resin Polymers 0.000 description 21
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 14
- 239000008267 milk Substances 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 108010076119 Caseins Proteins 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 235000021246 κ-casein Nutrition 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 239000000467 phytic acid Substances 0.000 description 4
- 229940068041 phytic acid Drugs 0.000 description 4
- 235000002949 phytic acid Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000006315 carbonylation Effects 0.000 description 3
- 238000005810 carbonylation reaction Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000021523 carboxylation Effects 0.000 description 3
- 238000006473 carboxylation reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000033444 hydroxylation Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 2
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 101100001708 Mus musculus Angptl4 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003226 decolorizating effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZQOILFFBJUNGRA-NMVUUJPQSA-N (4s)-4-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-[(2s)-2-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C ZQOILFFBJUNGRA-NMVUUJPQSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 102000009366 Alpha-s1 casein Human genes 0.000 description 1
- 108050000244 Alpha-s1 casein Proteins 0.000 description 1
- 108050001786 Alpha-s2 casein Proteins 0.000 description 1
- GDVDRMUYICMNFJ-CIUDSAMLSA-N Arg-Cys-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O GDVDRMUYICMNFJ-CIUDSAMLSA-N 0.000 description 1
- UPKMBGAAEZGHOC-RWMBFGLXSA-N Arg-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O UPKMBGAAEZGHOC-RWMBFGLXSA-N 0.000 description 1
- MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 1
- QCTOLCVIGRLMQS-HRCADAONSA-N Arg-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O QCTOLCVIGRLMQS-HRCADAONSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- NNMUHYLAYUSTTN-FXQIFTODSA-N Asn-Gln-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O NNMUHYLAYUSTTN-FXQIFTODSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- HRVQDZOWMLFAOD-BIIVOSGPSA-N Asp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)O HRVQDZOWMLFAOD-BIIVOSGPSA-N 0.000 description 1
- 101800002044 Casoxin-C Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- BVFQOPGFOQVZTE-ACZMJKKPSA-N Cys-Gln-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O BVFQOPGFOQVZTE-ACZMJKKPSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 description 1
- OREPWMPAUWIIAM-ZPFDUUQYSA-N Gln-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N OREPWMPAUWIIAM-ZPFDUUQYSA-N 0.000 description 1
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 1
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- GXMXPCXXKVWOSM-KQXIARHKSA-N Glu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N GXMXPCXXKVWOSM-KQXIARHKSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XIGFLVCAVQQGNS-IHRRRGAJSA-N His-Pro-His Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XIGFLVCAVQQGNS-IHRRRGAJSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RWIKBYVJQAJYDP-BJDJZHNGSA-N Ile-Ala-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RWIKBYVJQAJYDP-BJDJZHNGSA-N 0.000 description 1
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
- YGDWPQCLFJNMOL-MNXVOIDGSA-N Ile-Leu-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YGDWPQCLFJNMOL-MNXVOIDGSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000209499 Lemna Species 0.000 description 1
- WXHFZJFZWNCDNB-KKUMJFAQSA-N Leu-Asn-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXHFZJFZWNCDNB-KKUMJFAQSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
- YSPZCHGIWAQVKQ-AVGNSLFASA-N Lys-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN YSPZCHGIWAQVKQ-AVGNSLFASA-N 0.000 description 1
- QGQGAIBGTUJRBR-NAKRPEOUSA-N Met-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC QGQGAIBGTUJRBR-NAKRPEOUSA-N 0.000 description 1
- CRVSHEPROQHVQT-AVGNSLFASA-N Met-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N CRVSHEPROQHVQT-AVGNSLFASA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- AJLVKXCNXIJHDV-CIUDSAMLSA-N Pro-Ala-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O AJLVKXCNXIJHDV-CIUDSAMLSA-N 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- VTVVYQOXJCZVEB-WDCWCFNPSA-N Thr-Leu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O VTVVYQOXJCZVEB-WDCWCFNPSA-N 0.000 description 1
- UJQVSMNQMQHVRY-KZVJFYERSA-N Thr-Met-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UJQVSMNQMQHVRY-KZVJFYERSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- JLTQXEOXIJMCLZ-ZVZYQTTQSA-N Trp-Gln-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 JLTQXEOXIJMCLZ-ZVZYQTTQSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 235000019239 indanthrene blue RS Nutrition 0.000 description 1
- UHOKSCJSTAHBSO-UHFFFAOYSA-N indanthrone blue Chemical compound C1=CC=C2C(=O)C3=CC=C4NC5=C6C(=O)C7=CC=CC=C7C(=O)C6=CC=C5NC4=C3C(=O)C2=C1 UHOKSCJSTAHBSO-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YYVGYULIMDRZMJ-UHFFFAOYSA-N propan-2-ylsilane Chemical compound CC(C)[SiH3] YYVGYULIMDRZMJ-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 108010030651 valyl-glutamyl-prolyl-isoleucyl-prolyl-tyrosine Proteins 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to the field of protein, and in particular relates to a bioactive polypeptide ATLEDSPEVI, a preparation method and application thereof, wherein the amino acid sequence of the bioactive polypeptide ATLEDSPEVI is Ala-Thr-Leu-Glu-Asp-Ser-Pro-Glu-Val-Ile. In-vitro antioxidant experiments and in-vitro immune function promotion experiments prove that the polypeptide ATLEDSPEVI has better antioxidant biological activity and immune regulation function, on one hand, the polypeptide has better antioxidant activity, can remove free radicals in a body and improve the quality of life; on the other hand, the bioactive polypeptide ATLEDSPEVI can enhance the in vitro proliferation capacity of lymphocytes and macrophages, promote the macrophages to secrete cytokines, improve the capability of an organism to resist infection of external pathogens, reduce the morbidity of the organism and has very important significance for developing foods, health-care products and medicines with immune regulation functions and anti-oxidation functions.
Description
Technical Field
The invention relates to the field of proteins, in particular to a bioactive polypeptide ATLEDSPEVI, and a preparation method and application thereof.
Background
In the process of fermenting the cow milk by the lactic acid bacteria, a part of protein in the cow milk is metabolized and utilized by the lactic acid bacteria, and a series of physiological and biochemical reactions occur, so that the protein is changed into polypeptide or free amino acid which is digested and absorbed by a human body or directly enters the blood circulation of the human body through the absorption and transportation of small intestinal epithelial cells. Among these polypeptides, some have a specific physiological function and are called "bioactive peptides".
Oxidation reactions and oxidative metabolism are vital to food and the human body, and free radicals and active oxygen cause a series of oxidation reactions. When excessive free radicals are formed, they exceed the protective effects of protective enzymes such as superoxide dismutase, catalase, resulting in a series of side effects such as lipid oxidation, apoptosis, etc. The oxidation reaction not only affects the shelf life of the fat-containing food, but also causes certain harm to the health of human bodies, such as rheumatoid arthritis, diabetes, arteriosclerosis and the like. In addition, Collins et al, 2005 discovered that cancer development was also associated with oxidative damage to DNA.
Early synthetic antioxidants such as Butylated Hydroxyanisole (BHA), 2, 6-di-tert-butyl-4-methylphenol (BHT) were used in food as lipid antioxidants, but these synthetic additives all have potential risks to humans. Therefore, it is particularly important to find safe antioxidants in natural food sources. In recent years, it has been found that some food-derived polypeptides, such as short peptides of corn, soybean peptides, milk polypeptides, etc., have a good antioxidant effect. The polypeptides can be obtained through various ways such as microbial fermentation, digestion and enzymolysis and the like, and most of the polypeptides with antioxidant activity consist of 2-20 amino acid residues, have the molecular weight of less than 6000Da and contain a certain amount of hydrophobic amino acids and aromatic amino acids.
Immunoactive peptides are a class of bioactive polypeptides that are first obtained from milk following opioid peptide discovery and demonstrate their physiological activity. Jolles et al found in 1981 for the first time that a hexapeptide with an amino acid sequence Val-Glu-Pro-Ile-Pro-Tyr can be obtained by hydrolyzing human milk protein with trypsin, and in vitro experiments prove that the hexapeptide can enhance the phagocytosis of mouse abdominal cavity macrophages to sheep erythrocytes. Migliore-Samour et al found that the casein-derived hexapeptide Thr-Thr-Met-Pro-Leu-Trp was able to stimulate phagocytosis of murine peritoneal macrophages by sheep red blood cells and to enhance resistance to Klebsiella pneumoniae. Lemna hexandra et al, fed rats with synthetic milk-derived immunoregulatory peptide (PGPIPN), found that phagocytosis of macrophages in the abdominal cavity of rats and immunoregulatory function related to erythrocytes were significantly enhanced.
Researches show that the immune active peptide can not only enhance the immunity of the organism, stimulate the proliferation of lymphocytes of the organism, enhance the phagocytic function of macrophages, promote the release of cell factors, improve the capability of the organism for resisting the infection of external pathogens, reduce the morbidity of the organism, but also can not cause the immune rejection reaction of the organism.
At present, there are many researches on bioactive polypeptides, for example, chinese patent CN105254738A discloses a milk-derived bioactive polypeptide DELQDKIH derived from β -casein, chinese patent CN105254739A discloses a milk-derived bioactive polypeptide GTQYTD derived from α s 1-casein, and chinese patent CN105254740A discloses a milk-derived bioactive polypeptide NQFYQKF derived from α s 2-casein.
Disclosure of Invention
The invention aims to provide a bioactive polypeptide ATLEDSPEVI, and a preparation method and application thereof.
The purpose of the invention can be realized by the following technical scheme:
in a first aspect of the invention, there is provided a biologically active polypeptide ATLEDSPEVI having the amino acid sequence Ala-Thr-Leu-Glu-Asp-Ser-Pro-Glu-Val-Ile as set forth in SEQ ID NO: 1 is shown.
Preferably, the biologically active polypeptide is milk-derived. In particular to kappa-casein, and is the amino acid residue from 165 th to 174 th positions of a kappa-casein variant A. The amino acid sequence of the kappa-casein variant A is shown as SEQ ID NO: 3, respectively.
The amino acid sequence and the corresponding nucleotide sequence of the kappa-casein are the existing technology, and the nucleotide fragment which codes the 165 th to 174 th amino acid residues of the kappa-casein variant A can code mature bioactive polypeptide ATLEDSPEVI.
Preferably, the bioactive polypeptide has antioxidant and immunoregulatory functions.
In a second aspect of the present invention, there is provided a nucleotide fragment encoding the biologically active polypeptide ATLEDSPEVI, the sequence of which is: 5'-gct act cta gaa gat tct cca gaa gtt att-3', as shown in SEQ ID NO: 2, respectively.
In the third aspect of the present invention, a preparation method of the bioactive polypeptide ATLEDSPEVI is provided, which can be artificially synthesized by a genetic engineering method, can be directly obtained from a dairy product by a separation and purification method, and can be directly prepared by chemical synthesis.
In the fourth aspect of the invention, the application of the bioactive polypeptide ATLEDSPEVI in preparing food, health products, medicines or cosmetics with antioxidant function is provided.
In the fifth aspect of the invention, the application of the bioactive polypeptide ATLEDSPEVI in preparing food, health-care products or medicines with immunoregulation function is provided.
In a sixth aspect, the invention provides an application of the bioactive polypeptide ATLEDSPEVI in preparing food, health care products or medicines with antioxidant function and immunoregulation function.
Specifically, the bioactive polypeptide ATLEDSPEVI can be used for preparing cosmetics for reducing free radical damage to skin, and medicines for resisting oxidation and/or regulating immunity of organism; and because the product of the bioactive polypeptide ATLEDSPEVI degraded by gastrointestinal tract still has bioactivity, the bioactive polypeptide ATLEDSPEVI can be used for preparing foods such as yoghourt and health-care products for regulating immunity, and can be orally taken for preparing medicines for resisting oxidation and/or regulating organism immunity.
In a seventh aspect of the invention, there is provided an antioxidant product comprising said biologically active polypeptide ATLEDSPEVI or a derivative of said biologically active polypeptide ATLEDSPEVI; the antioxidant product comprises antioxidant food, antioxidant health product, antioxidant medicine or antioxidant cosmetic; the derivative of the biologically active polypeptide ATLEDSPEVI refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide ATLEDSPEVI.
In an eighth aspect of the invention, there is provided an immunomodulatory product comprising said biologically active polypeptide ATLEDSPEVI or a derivative of said biologically active polypeptide ATLEDSPEVI; the immunoregulation product comprises immunoregulation food, immunoregulation health-care products or immunoregulation medicines; the derivative of the biologically active polypeptide ATLEDSPEVI refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide ATLEDSPEVI.
In the ninth aspect of the present invention, a product having both antioxidant function and immunoregulatory function is provided, which comprises the bioactive polypeptide ATLEDSPEVI or a derivative of the bioactive polypeptide ATLEDSPEVI; products with antioxidant and immunoregulatory effects include foods, health products or pharmaceuticals; the derivative of the biologically active polypeptide ATLEDSPEVI refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide ATLEDSPEVI.
The bioactive polypeptide ATLEDSPEVI has the following beneficial effects: the milk-derived bioactive polypeptide ATLEDSPEVI has good antioxidant activity and activity for regulating the immunity of organisms; on one hand, the free radicals in the organism can be removed, and the harm of the free radicals to the human body is reduced; on the other hand, the bioactive polypeptide ATLEDSPEVI can also regulate the immunity of the organism, enhance the proliferation capacity of lymphocytes, improve the capability of the organism for resisting the infection of external pathogens, reduce the morbidity of the organism, and cannot cause the immune rejection reaction of the organism, thereby having very important significance for developing dairy products and health care products with the functions of resisting oxidation and regulating immunity.
Drawings
FIG. 1: mass chromatogram extraction (m/z 537.27);
FIG. 2: a primary mass spectrum of a fragment with a mass to charge ratio of 537.27;
FIG. 3: fragmentation of polypeptide az and by with mass-to-charge ratio of 537.27;
FIG. 4: [ DPPH. ] methanol Standard Curve;
FIG. 5: FeSO4A standard curve;
FIG. 6: an in vitro macrophage proliferation capacity test of the bioactive polypeptide ATLEDSPEVI;
FIG. 7: an IL-4 standard curve;
FIG. 8: the effect of the concentration of the cytokine IL-4 secreted by the biologically active polypeptide ATLEDSPEVI.
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, Sambrook et al: a LABORATORY MANUAL, Second edition, Cold Spring harbor LABORATORY Press, 1989and Third edition, 2001; ausubel et al, Current PROTOCOLS Inmolecular BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; wolffe, CHROMATINSTRUCUTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; (iii) Methods Inenzymolygy, Vol.304, Chromatin (P.M. Wassarman and A.P.Wolffe, eds.), academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol.119, chromatography protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999, etc.
The invention is described in detail below with reference to the figures and specific embodiments.
Example 1 Artificial Synthesis of active peptide ATLEDSPEVI
Synthesis of bioactive peptide
1.3 g of RINK resin (degree of substitution 0.3mmol/g) was weighed into a 150ml reactor and soaked with 50ml of Dichloromethane (DCM).
After 2.2 hours, the resin was washed with 3 resin volumes of N-Dimethylformamide (DMF) and then drained, and this was repeated four times and the resin was drained until use.
3. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection, the resin was washed four times with 3 resin volumes of DMF and then drained.
4. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
5. Weighing a proper amount of amino acid Ala and a proper amount of 1-hydroxy-benzotriazole (HOBT) into a 50ml centrifuge tube, adding 20ml of DMF to dissolve the amino acid Ala and the 1-hydroxy-benzotriazole (HOBT), then adding 3ml of N, N diisopropyl carbodiimide (DIC) to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor into a30 ℃ shaking table to react.
After 6.2 hours, the column was capped with a suitable amount of acetic anhydride (acetic anhydride: DIEA: DCM ═ 1:1:2, v: v: v) for half an hour, then washed four times with 3 resin volumes of DMF and drained until needed.
7. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection was washed four times with DMF and then drained.
8. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
9. Weighing a second proper amount of amino acid and a proper amount of HOBT in a 50ml centrifuge tube, adding 25ml of DMF to dissolve the amino acid and the HOBT, adding 2.5ml of DIC to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor in a shaking table at 30 ℃ to react.
After 10.1 hours, a small amount of resin is taken for detection, and the detection is carried out by an indanthrone method (two drops are respectively detected A and B, and the reaction is carried out for 1min at 100 ℃), if the resin is colorless, the reaction is complete; if the resin is colored, the condensation is not complete and the reaction is continued.
11. After the reaction was completed, the resin was washed four times with DMF and then drained, and a certain amount of 20% piperidine (piperidine/DMF ═ 1:4, v: v) was added to the reactor, and the mixture was shaken on a decolorizing shaker for 20min to remove the Fmoc-protecting group from the resin. After the protection is removed, washing with DMF for four times, and then draining to detect whether the protection is removed.
12. And sequentially grafting amino acids Thr, Leu, Glu, Asp, Ser, Pro, Glu, Val and Ile according to the steps 9-11.
13. After the last amino acid had been grafted, the protection was removed, washed four times with DMF and the resin was drained with methanol. The polypeptide was then cleaved from the resin with 95 cleavage medium (trifluoroacetic acid: 1,2 ethanedithiol: 3, isopropylsilane: water: 95:2:2:1, v: v: v) (10 ml of cleavage medium per gram of resin) and centrifuged four times with glacial ethyl ether (cleavage medium: ethyl ether: 1:9, v: v).
To this end, bioactive peptide ATLEDSPEVI was synthesized.
Confirmation of biologically active peptides
1) UPLC analysis
UPLC conditions were as follows:
the instrument comprises the following steps: waters ACQUITY UPLC ultra-high performance liquid-electrospray-quadrupole-time-of-flight mass spectrometer
Specification of chromatographic column: BEH C18 chromatographic column
Flow rate: 0.4mL/min
Temperature: 50 deg.C
Ultraviolet detection wavelength: 210nm
Sample introduction amount: 2 μ L
Gradient conditions: solution A: water containing 0.1% formic acid (v/v), liquid B: acetonitrile containing 0.1% formic acid (v/v)
2) Mass spectrometric analysis
The mass spectrometry conditions were as follows:
ion mode: ES +
Mass range (m/z): 100-1000
Capillary voltage (Capillary) (kV): 3.0
Sampling cone (V): 35.0
Ion source temperature (. degree. C.): 115
Desolvation temperature (. degree. C.): 350
Desolventizing gas stream (L/hr): 700.0
Collision energy (eV): 4.0
Scan time (sec): 0.25
Inner scan time (sec): 0.02
According to the above analysis method, ultra high performance liquid chromatography-electrospray-quadrupole-time-of-flight mass spectrometry is used to perform chromatographic analysis and mass spectrometry on bioactive peptide ATLEDSPEVI, the mass chromatogram extraction diagram is shown in FIG. 1, the primary and secondary mass spectrograms of the peak are shown in FIGS. 2 and 3, the polypeptide mass-to-charge ratio of the peak is 537.27Da, and the retention time is 18.21 min.
3) Results
As can be seen from FIG. 3, the fragment sequence with the mass-to-charge ratio of 537.27Da, which is obtained by analysis and calculation of Progenetics QI software according to the cases of az and by fragmentation, is Ala-Thr-Leu-Glu-Asp-Ser-Pro-Glu-Val-Ile (ATLEDSPEVI) and is shown as SEQ ID NO: 1. the fragment corresponds to residue sequences of 165 th to 174 th sites of a kappa-casein variant A, the GenBank number of a kappa-casein amino acid sequence is AAA30433.1, and the sequence is shown in SEQ ID NO: 3.
example 2 antioxidant Activity assay of bioactive peptides
The bioactive polypeptide ATLEDSPEVI obtained in example 1 was tested for antioxidant activity by free radical scavenging (DPPH & method) and total antioxidant activity (Ferric Reducing AbilityPower FRAP method).
1. [ DPPH ] method for determining in vitro antioxidant activity of bioactive peptide ATLEDSPEVI
1) Experimental reagent and instrument
Reagent: 1, 1-Diphenyl-2-trinitrophenylhydrazine (1, 1-Diphenyl-2-piperidinylhydrazyl [ DPPH. ]), manufactured by Wako corporation of Japan; methanol, available from Shanghai national drug company; milk-derived bioactive polypeptide ATLEDSPEVI obtained in example 1.
The main apparatus is as follows: sunrise microplate reader, available from Tecan, austria; 96-well cell culture plates, manufactured by Millipore, usa; analytical balance, product of Meitelei-tolido.
2) Experimental methods
(1)1mmol/L of [ DPPH. ] methanol solution
0.349mg of [ DPPH ] is weighed by an analytical balance and dissolved in 1mL of methanol solution to prepare 1mmol/L of [ DPPH ] methanol solution, and the tinfoil is stored away from light and ready to use.
(2) Determination of [ DPPH. ] methanol Standard Curve
Add 100 μ L [ DPPH. cndot. ] methanol standard curve sample into 96-well plate according to table 1, let stand for 90min at room temperature, and detect the absorbance at 517nm with enzyme-linked immunosorbent assay.
TABLE 1 [ DPPH. methanol Standard Curve solution preparation
From the experimental results, a curve was fitted using Excel and a regression equation was calculated, and the results are shown in fig. 4 (regression equation: y ═ 0.192x +0.2271, R2=0.9991)。[DPPH·]The linear relation of the methanol standard curve is good, the correlation coefficient is 0.999, and the result shows that [ DPPH ]]The precision and accuracy of the methanol standard curve meet the detection requirements. From the results, the absorbance value was compared with [ DPPH ]]The contents are in inverse proportion, [ DPPH ]]The lower the content, the higher the absorbance, i.e.the greater the ability of the sample to scavenge free radicals.
(3) Method for measuring antioxidant activity of bioactive peptide ATLEDSPEVIV by [ DPPH ]
1) Sample group: adding 80 μ L of 1mmol/L [ DPPH. cndot. ] methanol solution into a 96-well plate, and adding 20 μ L of samples to be tested (ATLEDSPEVI), positive control 1 (Trolox of 2.5 mg/mL), positive control 2 (Trolox of 0.025 mg/mL), and negative control (phytic acid) at different concentrations according to Table 2;
2) blank group: a blank was made on the same 96-well plate by adding 80. mu.L of a 1mmol/L [ DPPH. ] methanol solution and 20. mu.L of deionized water.
And (3) standing the sample to be detected for 90min at room temperature after the sample loading is finished, and detecting the light absorption value at 517nm by using an enzyme-labeling instrument. The radical scavenging rate was calculated according to the following formula and the experimental results are shown in table 2.
TABLE 2 determination of antioxidant Activity of bioactive Polypeptides by the DPPH method
As can be seen from Table 2, 2.5mg/mL of Trolox as a positive control had the strongest ability to scavenge free radicals under the same conditions, almost all free radicals in solution were scavenged, followed by 0.025mg/mL of Trolox, phytic acid, active polypeptide. The rate of the polypeptide ATLEDSPEVI for eliminating [ DPPH ] free radicals is inverted bell-shaped along with the change of concentration, and reaches the highest value at the concentration of 2.5mg/mL, which is 23.60%.
2. Method for measuring in-vitro antioxidant capacity of polypeptide in fermented milk by FARP (false positive RP) method
1) Experimental reagents and instruments
A total antioxidant capacity detection kit (a pharmaceutical Reducing activity of Plasma FRAP method) purchased from Shanghai Biyuntian Biotech company; FeSO4Solution (10mmol/L), water-soluble vitamin E (Trolox solution) (10mmol/L), milk-derived bioactive polypeptide ATLEDSPEVI obtained in example 1.
The main apparatus is as follows: sunrise microplate reader, available from Tecan, austria; 96-well cell culture plates, manufactured by Millipore, usa; analytical balance, product of Meitelei-tolido; HWS26 model electric heating constant temperature water bath, manufactured by Shanghai-constant technology, Inc.
2) Experimental methods
(1) Preparation of FRAP working solution
According to the total antioxidant capacity detection kit, 7.5mL of TPTZ diluent, 750 mu L of TPTZ solution and 750 mu L of detection buffer solution are uniformly mixed, incubated in a water bath at 37 ℃ and used up within 2 hours.
(2)FeSO4Preparation and determination of Standard Curve
Adding 180 mu LFRAP working solution into a 96-well plate, adding 5 mu L FeSO according to the table 34And (3) lightly mixing the standard curve solution, incubating for 3-5min at 37 ℃, and measuring the light absorption value at 593nm by using an enzyme-labeling instrument.
TABLE 3 FeSO4Solution formulation for standard curve determination
FeSO4The concentration and the light absorption value are in a good proportional relation, FeSO4The higher the concentration, the higher the absorbance. FeSO of the invention4The results of the standard curve are shown in FIG. 5, the linear relation of the standard curve is good, the correlation coefficient is 0.998, and the FeSO4The precision and accuracy of the standard curve meet the detection requirements, and can be used for subsequent calculation。
(3) FRAP method for determining antioxidant capacity of bioactive polypeptide ATLEDSPEVI
Adding 180 mu L of FRAP working solution into a 96-well plate, and adding 5 mu L of ddH into a blank control well2And O, adding 5 mu L of a sample to be detected into the sample detection hole and 5 mu L of phytic acid into the positive control, slightly mixing uniformly, incubating at 37 ℃ for 3-5min, and measuring the light absorption value at 593nm by using an enzyme-linked immunosorbent assay. Total antioxidant capacity is expressed as FeSO4The concentration of the standard solution. The radical clearance was calculated according to the following formula and the results are shown in Table 4.
TABLE 4 FARP method for determining the total antioxidant capacity of bioactive polypeptides in Lactobacillus helveticus fermented milk
The in vitro total antioxidant activity of the polypeptide ATLEDSPEVI is measured by a total antioxidant activity method (a Ferric Reducing activity Power FRAP method), and the bioactive polypeptide ATLEDSPEVI is found to have better capability of Reducing an oxidation substance; under the condition of concentration of 4mg/mL, the total antioxidant level of the polypeptide ATLEDSPEVI reaches 0.0231 mmol/g; the total antioxidant capacity of the bioactive polypeptide ATLEDSPEVI is proved to be higher than that of phytic acid with weak antioxidant activity under the same concentration, and the difference is significant (p is more than 0.05). Thus, the biologically active polypeptide ATLEDSPEVI of the invention was identified as having significant antioxidant capacity.
Example 3 Activity experiment of bioactive peptide for improving immunity
First, MTT method for testing in vitro lymphocyte proliferation capacity experiment of bioactive polypeptide ATLEDSPEVI
1) Experimental materials and instruments:
reagents and materials: experimental animals balb/c mice (male 6-8 weeks old, animal experiment center of Shanghai university of transportation, college of agriculture and biology); milk-derived bioactive polypeptide ATLEDSPEVI obtained in example 1; mouse lymphocyte extract (ex solibao); RPMI1640 medium (purchased from GIBCO); 3- (4, 5-Dimethylthiazol-2) -2, 5-diphenyltetrazolium bromide salt (MTT, available from Amresco, Inc.); concanavalin (ConA, available from Sigma); bovine serum albumin (BSA, available from Genebase); pepsin (available from Sigma); pancreatin (Corolase PP, from AB).
The instrument comprises the following steps: LRH-250F Biochemical incubator, Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge, shanghai luxiang instrument centrifuge instruments ltd; hera cell150CO 2 incubator, Heraeus; dragon wellscan mk3 microplate reader, Labsystems corporation; ALPHA 1-2-LD vacuum freeze drier, Christ company; ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometer, waters corporation.
2) The experimental method comprises the following steps:
taking mouse spleen under aseptic condition, extracting mouse lymphocyte with lymphocyte extract, and performing primary culture. The cell density was adjusted to 2.5X 10 with complete RPMI1640 medium6one/mL. To a 96-well cell culture plate were added in sequence: 100 μ L mouse lymphocyte suspension, 100 μ L RPMI1640 complete medium, 20 μ L concanavalin, 100 μ L sample. In addition, a blank control group (PBS with pH7.2-7.4 and 3 mol/L) and a negative control group (500 mu g/mL BSA) are arranged, and the research shows that the blank control group has no influence on the in vitro lymphocyte proliferation. Each set of 3 replicates. At 5% CO2Culturing at 37 deg.C for 68h, adding 20 μ L MTT into each well under aseptic condition, culturing for 4h, carefully removing supernatant, adding 100 μ L dimethyl sulfoxide into each well, incubating at 37 deg.C for 10min, shaking, and measuring absorbance at 570nm with microplate reader.
The in vitro lymphocyte proliferation capacity is expressed by a stimulation index and is calculated as follows:
in the formula: a. the1Absorbance at 570nm for the blank; a. the2Absorbance at 570nm for the negative control, A3The absorbance at 570nm for the experimental group.
3) Results and analysis of the experiments
The results are shown in Table 5. As can be seen from Table 5, under the condition that the mass concentration of the bioactive peptide ATLEDSPEVI is 100 μ g/mL, the stimulation index of the milk-derived bioactive peptide ATLEDSPEVI is greater than that of BSA, which indicates that ATLEDSPEVI can stimulate the proliferation of mouse lymphocytes in vitro to some extent. And ATLEDSPEVI reached a stimulation index of 1.166, which was significantly different from that of the negative control group (P < 0.05). Therefore, the active polypeptide ATLEDSPEVI can be considered to have the capacity of remarkably promoting the mouse lymphocyte proliferation, can be eaten as a health product or an additive, and can improve the immunity of animals and human bodies.
TABLE 5 Effect of biologically active polypeptide ATLEDSPEVI on in vitro lymphocyte proliferation
Experiment grouping | Stimulation index SI |
|
1 |
ATLEDSPEVI | 1.166±0.059* |
Note: the number marked as significant difference (P <0.05) compared to the negative control.
Second, MTT method for measuring in vitro macrophage proliferation ability experiment of bioactive polypeptide ATLEDSPEVI
1) Experimental reagent and instrument
Reagent: experimental animals balb/c mice (male 6-8 weeks old) were collected at the animal Experimental center of the college of agriculture and biology of Shanghai university of transportation; milk-derived bioactive polypeptide ATLEDSPEVI obtained in example 1; 3- (4, 5-Dimethylthiazol-2) -2, 5-diphenyltetrazolium bromide (MTT) Amresco; LPS (lipopolysaccharide) Sigma company; bovine Serum Albumin (BSA) Genebase; triple solutions, aqueous solutions containing 10% SDS, 5% isobutanol and 0.012mol/L HCl.
The instrument equipment comprises: LRH-250F Biochemical incubator Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge Shanghai Luxiang apparatus centrifuge Instrument Co., Ltd; hera cell150CO2Incubator Heraeus; dragon WellscanMK3 microplate reader Labsystems.
2) The test method comprises the following steps:
balb/c mice were injected intraperitoneally with 2ml of 2% (w/w) sterile starch solution for three consecutive days, and sacrificed by cervical dislocation 24 hours after the last injection. Peeling off the abdominal skin, sucking 4 ℃ Phosphate Buffer Solution (PBS) by using a syringe to repeatedly wash the abdominal cavity, centrifuging the washed solution by using a centrifuge tube for 10 minutes after collecting the washed solution, discarding the supernatant after centrifuging the washed solution (1000rpm and 4 ℃), washing the washed solution twice by using 4 ℃ RPMI1640 complete culture solution (containing 10% FBS), staining the washed solution by using 0.2% trypan blue solution to detect the vitality of the cells, and confirming that the collected viable macrophages account for more than 95%. After reading the cell counting plate, the cell concentration was adjusted to the appropriate concentration.
The cell suspension that had been blown to complete suspension was added to a 96-well cell culture plate at 37 ℃ with 5% CO in an appropriate volume2After culturing for 4 hours under the environment, removing liquid in the holes, carefully cleaning the bottom of the holes of the cell culture plate by using a complete culture solution RPMI1640 at 37 ℃, and washing the cells and cell fragments which are not attached to the walls to obtain the purified attached abdominal cavity macrophages. 0.2ml of RPMI1640 complete medium was added to each well, and the small peptide sample for experiment and LPS were dissolved in the medium in advance and then added to start cell culture.
The number of the added cells was 2X 105100 μ l/well of cell suspension/mL, 200 μ l/well of RPMI1640 complete medium (10% FBS) containing bioactive polypeptide (100, 500, 1000 μ g/mL) was added after adherent purification, and cultured continuously for 48 hours, and LPS was added to the inflammatory group at 24 hours to a final concentration of 100 ng/mL. 5% MTT 20. mu.l/well was added at 44 hours, and 100. mu.l/well triple lysis buffer was added to stop the incubation after 48 hoursAfter the overnight dissolution, the absorbance (OD570) of each well was measured at a wavelength of 570nm with a microplate reader, and the Growth index (Growth Indices) was calculated as follows:
among them, the blank group was a cell-treated group to which no small peptide and BSA were applied, and the BSA group was a negative control.
3) Results of the experiment
The results are shown in FIG. 6, in which the bioactive polypeptide (ATLEDSPEVI) was added at concentrations of 1000, 500, and 100. mu.g/mL in the experimental group, and the blank group was added with a corresponding amount of PBS as a blank control, indicating the proliferation of macrophages in the absence of LPS stimulation. Compared with a blank control group, the experimental group added with the polypeptide ATLEDSPEVI with different concentrations has the characteristic that the proliferation capacity of macrophages is gradually increased along with the increase of the experimental concentration, and has a significant difference (P <0.05) when the concentration is 1000 and 500 mu g/mL. Indicating that the biologically active polypeptide ATLEDSPEVI has the ability to promote macrophage proliferation.
Third, the experiment (ELISA method) of promoting macrophage to secrete cytokine of the biological activity polypeptide ATLEDSPEVI
1. Experimental reagent and equipment
1) Reagent: experimental animals balb/c mice (male 6-8 weeks old), Shanghai Slek Experimental animals, Inc.; mouse lymphocyte extract, shanghai solibao biotechnology limited; RPMI1640 medium, GIBCO; bovine Serum Albumin (BSA), Genebase; milk-derived bioactive polypeptide ATLEDSPEVI obtained in example 1; ELISA cytokine Rapid kit (IL-4), Wuhan doctor De bioengineering, Inc.
2) Instrumentation and equipment
Model CM-230 Mohr super Water, Shanghai Mole scientific instruments, Inc.; LRH-250F Biochemical incubator, Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge, shanghai luxiang instrument centrifuge instruments ltd; hera cell150CO2Incubator, Heraeus corporation; dragon Wellscan MK3 microplate reader, Labsystems Inc.
2. Test method
1) Preparation of the Standard Curve
Making an IL-4 standard curve: IL-4 standard substances with the concentrations of 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.3pg/mL, 15.6pg/mL and 7.8pg/mL are respectively and sequentially added into the holes of the ELISA plate, then biotin-labeled anti-mouse IL-4 antibody (ELISA cytokine rapid kit) is added, the ELISA plate is covered, and the reaction is carried out for 90min at 37 ℃. And (3) throwing off liquid in the ELISA plate, and sequentially adding 0.1mL of avidin-peroxidase complex (ELISA cytokine rapid kit) into each hole. The reaction was carried out at 37 ℃ for 60 min. 0.01M PBS was washed 3 times, and 0.1mL of ABC working solution was added to each well and reacted at 37 ℃ for 30 min. Washing with 0.01M PBS for 5 times, adding 90ul of TMB color development solution into each well, and reacting at 37 deg.C in dark for 25 min. 0.1mL of TMB stop solution was added to each well, and the absorbance was measured at 450nm using a microplate reader. The standard curve for IL-4 detection was prepared as shown in FIG. 7. The IL-4 standard curve was fitted by first regression using the concentration as abscissa (unit pg/mL) and the absorbance at 450nm as ordinate to obtain a standard curve Y of 0.0038X +0.1224, R20.9979. Wherein X represents the IL-4 concentration in pg/mL and Y represents the absorbance at OD 450.
2) Macrophage secretion promoting cytokine detection of polypeptide ATLEDSPEVI
Taking mouse spleen lymphocytes under aseptic condition, adjusting cell concentration to 5 × 105The cells were inoculated in a 96-well plate, and the test group was cultured by adding ATLEDSPEVI, adjusting the final concentrations of ATLEDSPEVI to 100, 50 and 10. mu.g/mL, respectively, and then cultured with lymphocytes for 36 hours to measure the cytokine IL-4. The blank group was incubated for 36h without the addition of the biologically active polypeptide ATLEDSPEVI as a control.
3. Results of the experiment
The experimental results are shown in FIG. 8, and compared with the blank control group, the secretion amount of IL-4 is gradually increased along with the increase of the polypeptide concentration; when the polypeptide addition concentration reaches 50 and 100 mu g/mL, the IL-4 secretion amount is obviously greater than that of a blank group; therefore, the bioactive polypeptide ATLEDSPEVI has the function of promoting lymphocyte proliferation, and has the function of regulating humoral immunity of the organism through regulating the secretion of IL-4 cytokines.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
<110> Zhejiang ghui peptide Life health science and technology Limited
<120> a bioactive polypeptide ATLEDSPEVI, and its preparation method and application
<160>3
<170>PatentIn version 3.3
<210>1
<211>10
<212>PRT
<213> Artificial sequence
<220>
<223> biologically active polypeptide
<400>1
Ala Thr Leu Glu Asp Ser Pro Glu Val Ile
5 10
<210>2
<211>30
<212>DNA
<213> Artificial sequence
<220>
<223> bioactive polypeptide coding sequence
<400>2
gctactctag aagattctcc agaagttatt 30
<210>3
<211>190
<212>PRT
<213> Artificial sequence
<220>
<223> kappa-Casein variant A amino acid sequence
<400>3
Met Met Lys Ser Phe Phe Leu Val Val Thr Ile Leu Ala Leu Thr
5 10 15
Leu Pro Phe Leu Gly Ala Gln Glu Gln Asn Gln Glu Gln Pro Ile
20 25 30
Arg Cys Glu Lys Asp Glu Arg Phe Phe Ser Asp Lys Ile Ala Lys
35 40 45
Tyr Ile Pro Ile Gln Tyr Val Leu Ser Arg Tyr Pro Ser Tyr Gly
50 55 60
Leu Asn Tyr Tyr Gln Gln Lys Pro Val Ala Leu Ile Asn Asn Gln
65 70 75
Phe Leu Pro Tyr Pro Tyr Tyr Ala Lys Pro Ala Ala Val Arg Ser
80 85 90
Pro Ala Gln Ile Leu Gln Trp Gln Val Leu Ser Asn Thr Val Pro
95 100 105
Ala Lys Ser Cys Gln Ala Gln Pro Thr Thr Met Ala Arg His Pro
110 115 120
His Pro His Leu Ser Phe Met Ala Ile Pro Pro Lys Lys Asn Gln
125 130 135
Asp Lys Thr Glu Ile Pro Thr Ile Asn Thr Ile Ala Ser Gly Glu
140 145 150
Pro Thr Ser Thr Pro Thr Thr Glu Ala Val Glu Ser Thr Val Ala
155 160 165
Thr Leu Glu Asp Ser Pro Glu Val Ile Glu Ser Pro Pro Glu Ile
170 175 180
Asn Thr Val Gln Val Thr Ser Thr Ala Val
185 190
Claims (9)
1. A bioactive polypeptide ATLEDSPEVI, characterized in that its amino acid sequence is Ala-Thr-Leu-Glu-Asp-Ser-Pro-Glu-Val-Ile.
2. A nucleotide fragment encoding the biologically active polypeptide ATLEDSPEVI of claim 1, wherein the nucleotide fragment has the sequence set forth in SEQ ID NO: 2, respectively.
3. The method of claim 1, wherein the biologically active polypeptide ATLEDSPEVI is synthesized by genetic engineering methods or is prepared directly by chemical synthesis.
4. The use of the biologically active polypeptide ATLEDSPEVI of claim 1, wherein the biologically active polypeptide ATLEDSPEVI is used in the preparation of a food, a health product, a pharmaceutical or a cosmetic product with antioxidant activity.
5. The use of the biologically active polypeptide ATLEDSPEVI of claim 1, wherein the biologically active polypeptide ATLEDSPEVI is used in the preparation of a food, a health product or a pharmaceutical product with immunomodulatory activity.
6. The use of the biologically active polypeptide ATLEDSPEVI of claim 1, wherein the biologically active polypeptide ATLEDSPEVI is used in the preparation of a food, a health product or a pharmaceutical product with antioxidant and immunomodulatory effects.
7. An antioxidant product comprising the biologically active polypeptide ATLEDSPEVI of claim 1; the antioxidant product comprises antioxidant food, antioxidant health product, antioxidant medicine or antioxidant cosmetic.
8. An immunomodulatory product comprising the biologically active polypeptide ATLEDSPEVI of claim 1; the immunoregulation product comprises immunoregulation food, immunoregulation health-care products or immunoregulation medicines.
9. A product having antioxidant and immunomodulating properties, comprising the biologically active polypeptide ATLEDSPEVI of claim 1; the product with antioxidant and immunoregulatory effects comprises food, health product or medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710480369.0A CN107141346B (en) | 2017-06-22 | 2017-06-22 | Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710480369.0A CN107141346B (en) | 2017-06-22 | 2017-06-22 | Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107141346A CN107141346A (en) | 2017-09-08 |
CN107141346B true CN107141346B (en) | 2020-04-14 |
Family
ID=59781850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710480369.0A Active CN107141346B (en) | 2017-06-22 | 2017-06-22 | Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107141346B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107840878A (en) * | 2017-11-14 | 2018-03-27 | 上海交通大学 | A kind of biologically active polypeptide NNQFLPYPYYAKPA and its preparation method and application |
CN107840882A (en) * | 2017-11-14 | 2018-03-27 | 上海交通大学 | A kind of biologically active polypeptide DIPNPIGSE and its preparation method and application |
CN107903314A (en) * | 2017-11-14 | 2018-04-13 | 上海交通大学 | A kind of biologically active polypeptide EVIESPPEINTV and its preparation method and application |
CN107827972A (en) * | 2017-12-11 | 2018-03-23 | 浙江辉肽生命健康科技有限公司 | A kind of biologically active polypeptide SPEVIESPPEIN and its preparation method and application |
CN109234343B (en) * | 2018-09-30 | 2020-12-01 | 中国海洋大学 | Methionine oligopeptide and preparation method and application thereof |
CN112625113B (en) * | 2020-12-16 | 2022-03-29 | 熊猫乳品集团股份有限公司 | Bioactive peptide AGYDVEKNNSRIKLGLK, and preparation method and application thereof |
CN112778410B (en) * | 2021-01-19 | 2022-05-31 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide SAPRHGSLGFLPRK, and preparation method and application thereof |
CN112724237B (en) * | 2021-01-19 | 2022-05-31 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide GGSDGYGSGRGF, and preparation method and application thereof |
CN116444612A (en) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | Milk active peptide APADPGRPTGY and preparation method and application thereof |
CN116444609A (en) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | Milk active peptide LPPPLPSRWPL and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10050091A1 (en) * | 2000-10-09 | 2002-04-25 | Biotechnolog Forschung Gmbh | New casein-derived peptide with growth promoting activity, useful as additive for eukaryotic cell cultures and for recombinant protein production |
EP2253324A1 (en) * | 2009-04-30 | 2010-11-24 | Consejo Superior De Investigaciones Cientificas | Use of a casein-derived peptide and compositions thereof as antihypertensive |
CN107163129B (en) * | 2014-12-19 | 2019-12-24 | 浙江辉肽生命健康科技有限公司 | Preparation and application of kappa-casein-derived bioactive peptide |
CN105254714B (en) * | 2015-10-16 | 2019-09-10 | 中国农业大学 | A kind of anti-oxidation peptide and application from casein |
-
2017
- 2017-06-22 CN CN201710480369.0A patent/CN107141346B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107141346A (en) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107141346B (en) | Bioactive polypeptide ATLEDSPEVI, and preparation method and application thereof | |
CN107226860B (en) | Bioactive polypeptide SKHSSLDCVL, and preparation method and application thereof | |
CN107176995B (en) | Bioactive polypeptide SKVLPVPEKAVPYPQ, and preparation method and application thereof | |
CN107177000B (en) | Bioactive polypeptide DRAAHVKQVL, and preparation method and application thereof | |
CN107226857B (en) | Bioactive polypeptide TIASGEPT and preparation method and application thereof | |
CN107163136B (en) | Bioactive polypeptide WNIPMGLIVNQ, and preparation method and application thereof | |
CN107236031B (en) | Bioactive polypeptide PMIGVNQELAY, and preparation method and application thereof | |
CN107200782B (en) | Bioactive polypeptide VAVVKKGSNFQ, and preparation method and application thereof | |
CN107188949B (en) | Bioactive polypeptide EINTVQVTST, and preparation method and application thereof | |
CN110938129B (en) | Bioactive polypeptide SKLVPVGYGIRKL, and preparation method and application thereof | |
CN110938130A (en) | Bioactive polypeptide RVFQPLPHENKPLTL, and preparation method and application thereof | |
CN108794598B (en) | Bioactive polypeptide NARIQDNLYLAV, and preparation method and application thereof | |
CN108794590B (en) | Bioactive polypeptide EPGIVNLD and preparation method and application thereof | |
CN108794593B (en) | Bioactive polypeptide GSVNDVQ and preparation method and application thereof | |
CN108794587B (en) | Bioactive polypeptide KVTPYQA and preparation method and application thereof | |
CN108794603B (en) | Bioactive polypeptide TVTMLMTTIL, and preparation method and application thereof | |
CN108558991B (en) | Bioactive polypeptide GIQDPKEP and preparation method and application thereof | |
CN111100196A (en) | Bioactive polypeptide QILSVPGWTYSR, and preparation method and application thereof | |
CN107903316B (en) | Bioactive polypeptide LPYPYYA and preparation method and application thereof | |
CN108017707B (en) | Bioactive polypeptide QPVLGPVRGP, and preparation method and application thereof | |
CN110922473B (en) | Bioactive polypeptide KDSNNLCLHFNPRFN, and preparation method and application thereof | |
CN107880107B (en) | Bioactive polypeptide QVLSNTVPA, and preparation method and application thereof | |
CN108794592B (en) | Bioactive polypeptide NAGVLQDIRFKQ, and preparation method and application thereof | |
CN109180782B (en) | Bioactive polypeptide DDVTEVM and preparation method and application thereof | |
CN108017703B (en) | Bioactive polypeptide VPITPT L N and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |